

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ERYSENG PARVO suspension for injection for pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 2 ml contains:

### Active substances:

Inactivated porcine parvovirus, strain NADL-2,..... RP > 1.15 \*

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,..... ELISA > 3.34 log<sub>2</sub> IE<sub>50%</sub>\*\*

\* RP – relative potency (ELISA).

\*\* IE<sub>50%</sub> – Inhibition ELISA 50%.

### Adjuvants:

Aluminium hydroxide ..... 5.29 mg (aluminium)

DEAE-Dextran

Ginseng.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Suspension for injection

Whitish suspension

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Pigs

### 4.2 Indications for use, specifying the target species

For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.

For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by *Erysipelothrix rhusiopathiae*, serotype 1 and serotype 2.

Onset of immunity:

Porcine parvovirus: from the beginning of the gestation period.

*E. rhusiopathiae*: three weeks after completion of the basic vaccination scheme.

Duration of immunity:

Porcine parvovirus: vaccination provides foetal protection for the duration of gestation.

Revaccination should be performed prior to each gestation, refer to section 4.9.

*E. rhusiopathiae*: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme), refer to section 4.9.

### **4.3 Contraindications**

Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Vaccinate healthy animals only.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of adverse reactions following accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### **4.6 Adverse reactions (frequency and seriousness)**

Very common adverse reactions:

- Mild to moderate inflammation at the injection site that typically resolves within four days but in some cases may persist for up to 12 days post-vaccination.

Common adverse reactions:

- A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

### **4.7 Use during pregnancy, lactation or lay**

Can be used during pregnancy and lactation.

### **4.8 Interaction with other medicinal products and other forms of interaction**

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with UNISTRAN PRRS (where this vaccine is authorised) and administered at one injection site. The product information of UNISTRAN PRRS should be consulted before administration of the mixed products.

The mixed administration of UNISTRAN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.

For mixed use the onset and duration of immunity of the parvovirus component and the onset of immunity of the *Erysipelas* component have been demonstrated to be equivalent to those determined

for ERYSENG PARVO when used alone. However, the duration of immunity of the *Erysipelas* component following mixed use has not been investigated.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

##### Basic vaccination:

Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3–4 weeks. The second injection should be administered 3–4 weeks before mating.

##### Revaccination:

A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months).

For simultaneous use with UNISTRRAIN PRRS in sows for reproduction from 6 months of age, the mixed administration of ERYSENG PARVO and UNISTRRAIN PRRS should only be used when vaccinating animals prior to mating.

The following instructions should be used: the contents of a single vial of UNISTRRAIN PRRS should be reconstituted with the contents of a single vial of ERYSENG PARVO. A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use.

UNISTRRAIN PRRS		ERYSENG PARVO
10 doses	+	10 doses (20 ml)
25 doses	+	25 doses (50 ml)
50 doses	+	50 doses (100 ml)

Allow the vaccine to reach room temperature (15–25 °C) before administration.  
Shake well before use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No adverse reactions other than those mentioned in section 4.6 were observed after the administration of a 2-fold vaccine dose.

#### **4.11 Withdrawal period(s)**

Zero days.

## **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Inactivated viral and bacterial vaccines for pigs.  
ATCvet code: QI09AL01.

To stimulate active immunisation against porcine parvovirus and swine erysipelas.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Aluminium hydroxide  
DEAE-dextran  
Disodium phosphate dodecahydrate  
Ginseng  
Potassium chloride  
Potassium dihydrogen phosphate  
Simethicone  
Sodium chloride  
Sodium hydroxide  
Water for injections

### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product, except with UNISTRAIN PRRS.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: use immediately.  
Shelf life after mixing with UNISTRAIN PRRS: 2 hours.

### **6.4. Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

### **6.5 Nature and composition of immediate packaging**

Type I colourless glass vials of 20, 50 and 100 ml.  
Polyethylene (PET) bottles of 20, 50, 100 and 250 ml.  
The vials are closed with a rubber stopper and aluminium cap.

#### Pack sizes:

Cardboard box with 1 glass vial of 10 doses (20 ml).  
Cardboard box with 1 glass vial of 25 doses (50 ml).  
Cardboard box with 1 glass vial of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 10 doses (20 ml).  
Cardboard box with 1 PET bottle of 25 doses (50 ml).  
Cardboard box with 1 PET bottle of 50 doses (100 ml).  
Cardboard box with 1 PET bottle of 125 doses (250 ml).

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/14/167/001-007

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 08/07/2014

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **ANNEX II**

- A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturers of the biological active substances:

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

LABORATORIOS HIPRA, S.A.  
Carretera C-63, km 48.300,  
Polígono Industrial El Rieral  
17170 Amer (Girona)  
SPAIN

Name and address of the manufacturer responsible for batch release:

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE**

**Cardboard box,  
Bottles (100 ml, 250 ml) and vials (100 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG PARVO suspension for injection for pigs

**2. STATEMENT OF ACTIVE SUBSTANCES**

Inactivated porcine parvovirus, strain NADL-2,..... RP > 1.15,  
inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,..... ELISA > 3.34 log<sub>2</sub> IE<sub>50%</sub>.

**3. PHARMACEUTICAL FORM**

Suspension for injection.

**4. PACKAGE SIZE**

10 doses (20 ml)  
25 doses (50 ml)  
50 doses (100 ml)  
125 doses (250 ml)

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intramuscular use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}  
Once broached use immediately.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated.  
Do not freeze.  
Protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read the package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/14/167/001  
EU/2/14/167/002  
EU/2/14/167/003  
EU/2/14/167/004  
EU/2/14/167/005  
EU/2/14/167/006  
EU/2/14/167/007

**17. MANUFACTURER’S BATCH NUMBER**

Batch

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Bottles, (20 ml, 50 ml) and vials (20 ml, 50 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG PARVO suspension for injection for pigs

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Inactivated porcine parvovirus, strain NADL-2,..... RP > 1.15,  
inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,..... ELISA > 3.34 log<sub>2</sub> IE<sub>50%</sub>.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 doses (20 ml)  
25 doses (50 ml)

**4. ROUTE(S) OF ADMINISTRATION**

IM

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Batch

**7. EXPIRY DATE**

EXP {month/year}  
Once broached use immediately.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:  
ERYSENG PARVO suspension for injection for pigs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

LABORATORIOS HIPRA, S.A.

Avda. la Selva, 135

17170 Amer (Girona)

SPAIN

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG PARVO suspension for injection for pigs

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One dose (2 ml) contains:

Inactivated porcine parvovirus, strain NADL-2,..... RP\* > 1.15,

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,..... ELISA > 3.34 log<sub>2</sub> IE<sub>50%</sub>\*\*

\* RP – relative potency (ELISA).

\*\* IE<sub>50%</sub> – Inhibition ELISA 50%.

Aluminium hydroxide .....5.29 mg (aluminium)

DEAE-Dextran

Ginseng.

Whitish suspension for injection.

**4. INDICATION(S)**

For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.

For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by *Erysipelothrix rhusiopathiae*, serotype 1 and serotype 2.

Onset of immunity:

Porcine parvovirus: from the beginning of the gestation period.

*E. rhusiopathiae*: three weeks after completion of the basic vaccination scheme.

Duration of immunity:

Porcine parvovirus: vaccination provides foetal protection for the duration of gestation. Revaccination should be performed prior to each gestation, refer to section “Dosage for each species, route(s) and method of administration”.

*E. rhusiopathiae*: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme), refer to section “Dosage for each species, route(s) and method of administration”.

## **5. CONTRAINDICATIONS**

Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients.

## **6. ADVERSE REACTIONS**

Very common adverse reactions:

- Mild to moderate inflammation at the injection site that typically resolves within four days but in some cases may persist for up to 12 days post-vaccination.

Common adverse reactions:

- A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Pigs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

### Basic vaccination:

Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3–4 weeks. The second injection should be administered 3–4 weeks before mating.

### Revaccination:

A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months).

For simultaneous use with UNISTRAN PRRS in sows for reproduction from 6 months of age, the mixed administration of ERYSENG PARVO and UNISTRAN PRRS should only be used when vaccinating animals prior to mating.

The following instructions should be used: the contents of a single vial of UNISTRAN PRRS should be reconstituted with the contents of a single vial of ERYSENG PARVO. A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use.



UNISTRRAIN PRRS		ERYSENG PARVO
10 doses	+	10 doses (20 ml)
25 doses	+	25 doses (50 ml)
50 doses	+	50 doses (100 ml)

## **9. ADVICE ON CORRECT ADMINISTRATION**

Allow the vaccine to reach room temperature (15–25 °C) before administration.  
Shake well before use.

## **10. WITHDRAWAL PERIOD(S)**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

Shelf life after first opening the container: use immediately.

Shelf life after mixing with UNISTRRAIN PRRS: 2 hours.

## **12. SPECIAL WARNING(S)**

Special precautions for use in animals:

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of adverse reactions following accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with UNISTRRAIN PRRS (where this vaccine is authorised) and administered at one injection site. The product information of UNISTRRAIN PRRS should be consulted before administration of the mixed products.

The mixed administration of UNISTRRAIN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.

For mixed use the onset and duration of immunity of the parvovirus component and the onset of immunity of the *Erysipelas* component have been demonstrated to be equivalent to those determined for ERYSENG PARVO when used alone. However, the duration of immunity of the *Erysipelas* component following mixed use has not been investigated.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

No adverse reactions other than already mentioned under section “Adverse reactions” can be expected after the administration of a 2-fold vaccine dose.

Incompatibilities:

Do not mix with any other veterinary medicinal product except with UNISTRAIN PRRS.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**15. OTHER INFORMATION**

Pack sizes:

Cardboard box with 1 glass vial of 10 doses (20 ml).

Cardboard box with 1 glass vial of 25 doses (50 ml).

Cardboard box with 1 glass vial of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 10 doses (20 ml).

Cardboard box with 1 PET bottle of 25 doses (50 ml).

Cardboard box with 1 PET bottle of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 125 doses (250 ml).

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

<p><b>Österreich</b>  HIPRA DEUTSCHLAND GmbH  Münsterstraße 306  40470 Düsseldorf  DEUTSCHLAND  e-mail: deutschland@hipra.com</p>	<p><b>België/Belgique/Belgien</b>  HIPRA BENELUX NV  Adequat Business Center  Brusselsesteenweg 159  9090 Melle  e-mail: benelux@hipra.com</p>
<p><b>Deutschland</b>  HIPRA DEUTSCHLAND GmbH  Münsterstraße 306  40470 Düsseldorf  e-mail: deutschland@hipra.com</p>	<p><b>Ελλάδα</b>  HIPRA ΕΛΛΑΣ Α.Ε.  Ψυχάρη 3 / 184 53 Νίκαια  Τηλ: 210 4978660 - Fax: 210 4978661  e-mail: greece@hipra.com</p>
<p><b>España</b>  LABORATORIOS HIPRA, S.A.  Avda. la Selva, 135  17170 Amer (Girona)</p>	<p><b>France</b>  HIPRA FRANCE  7 rue Roland Garros, Batiment H  44700 - Orvault  Tél. - 02 51 80 77 91 Fax - 02 51 8082 20  e-mail: france@hipra.com</p>
<p><b>Ireland</b>  HIPRA UK AND IRELAND, Ltd.  Innovation Center  BioCity Nottingham  Pennyfoot Street  Nottingham  NG1 1GF - UNITED KINGDOM  e-mail: ukandireland@hipra.com</p>	<p><b>Italia</b>  Hipra Italia S.r.l.  Via Rovato, 29  25030 Erbusco (BS)  e-mail: italia@hipra.com</p>
<p><b>Luxembourg</b>  HIPRA BENELUX NV  Adequat Business Center  Brusselsesteenweg 159  9090 Melle  BELGIUM  e-mail: benelux@hipra.com</p>	<p><b>Netherland</b>  HIPRA BENELUX NV  Adequat Business Center  Brusselsesteenweg 159  9090 Melle  BELGIUM  e-mail: benelux@hipra.com</p>
<p><b>Polska</b>  HIPRA POLSKA Sp.z.o.o.  Ul. Królowej Marysieńki, 9 - 1  02-954 – WARSZAWA  e-mail: admin.polska@hipra.com</p>	<p><b>Portugal</b>  ARBUSET, Produtos Farmacêuticos e Sanitários  De Uso Animal, Lda  Portela de Mafra e Fontáinha - Abrunheira  2665 – 191 Malveira  e-mail: portugal@hipra.com</p>
<p><b>United Kingdom</b>  HIPRA UK AND IRELAND, Ltd.  Innovation Center  BioCity Nottingham  Pennyfoot Street  Nottingham  NG1 1GF  e-mail: ukandireland@hipra.com</p>	